News

Pergoveris is a combination of recombinant human follicle stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) delivered through subcutaneous injection. The multi-center, randomized, controlled, single-blind, parallel Espart

The approval marks a major step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years. Pfizer acquired

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) had already issued a positive opinion for Latuda in January 2014. Latuda is an atypical

The topic of the Conference was "Different perspectives – one vision: Better healthcare for patients". The Conference helped professionals in the field of medicines, medical device, medical technology,

The uniqueness of this vaccine is that it is produced in ciliates and covers nearly all variations of a certain parasite antigen – a worldwide novelty. This project

The capacity expansion at the plant will help in providing a reliable supply of high-quality products to meet the domestic demand for the company’s products including cardiovascular and

The prospective, randomized, double-blind, placebo-controlled Phase IIa trial is designed to enroll up about 24 patients with type 1 diabetes in-clinic for ten days. During the trial, patients

CSG is nephrology academic research organization with 300 affiliated clinics worldwide, while Medpace is contract research organization (CRO) with demonstrated expertise and experience in nephrology. NRX expects to

Currently, BUNAVAIL is under review at the US Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of 07 June 2014. If BUNAVAIL